Steven Cohen Exelixis, Inc. Call Options Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $29 Million - $32.7 Million	1,596,600 Added 159.66%	2,596,600 $49.6 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $16.3 Million - $19.4 Million	1,000,000 New	1,000,000 $19.4 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $6.98 Million - $9.29 Million	410,000 New	410,000 $9.3 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.